A Sacrococcygeal Teratoma (SCT) is a rare medical miracle that occurs in newborn babies, usually in the first month of life. It is an abnormal growth that develops in the area of the baby’s tailbone. It is most often benign, meaning it is non-cancerous, but can also be malignant, or cancerous. In either case, it is a medical emergency that requires immediate attention. SCTs are classified as either type 1 or type 2. Type 1 SCTs are typically benign and occur in the lower portion of the tailbone. Type 2 SCTs are more likely to be malignant and occur higher up in the tailbone. Both types can cause serious health problems for the baby, including breathing difficulties, developmental delays, and even death.
The exact cause of SCT is unknown, but it is believed to be related to genetic factors. It is also thought that environmental factors, such as exposure to certain chemicals or radiation, may play a role.
SCTs are diagnosed through a physical exam and imaging tests such as ultrasound or magnetic resonance imaging (MRI). Treatment depends on the size and type of the tumor, as well as the age and overall health of the baby. For type 1 SCTs, the tumor is usually surgically removed. In some cases, chemotherapy or radiation may be used to shrink the tumor before surgery. For type 2 SCTs, the tumor may be treated with chemotherapy or radiation, or the entire tumor may be surgically removed.
The outlook for babies with SCTs is generally good. With prompt diagnosis and treatment, most babies make a full recovery. However, there is a risk of complications, including infection, bleeding, and organ damage. In some cases, the tumor may recur or spread to other parts of the body.
A Sacrococcygeal Teratoma is a rare medical miracle that can occur in newborn babies. It is classified as either type 1 or type 2, with type 1 being the more common and benign form. Diagnosis and treatment depend on the size and type of the tumor, as well as the age and overall health of the baby. With prompt diagnosis and treatment, most babies make a full recovery, although there is a risk of complications.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation